Free
Meeting Abstracts  |   April 1995
Glycine Receptor Antagonism: Effects of ACEA-1021 on the Minimum Alveolar Concentration for Halothane in the Rat
Author Notes
  • (McFarlane, Dexter) Associate, Department of Anesthesiology, University of Iowa.
  • (Warner) Professor, Department of Anesthesiology, Duke University Medical Center.
  • (Nader) Research Fellow, Department of Anesthesiology, University of Iowa.
  • Received from the Department of Anesthesia, University of Iowa College of Medicine, Iowa City, Iowa, and the Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina. Submitted for publication July 14, 1994. Accepted for publication December 12, 1994. Supported by United States Public Health Service grant ROI GM 39771. Presented at the annual meeting of the American Society of Anesthesiologists, October 1994.
  • Address reprint requests to Dr. Warner: Department of Anesthesiology, Duke University Medical Center, Box 3094, Durham, North Carolina 27710.
Article Information
Meeting Abstracts   |   April 1995
Glycine Receptor Antagonism: Effects of ACEA-1021 on the Minimum Alveolar Concentration for Halothane in the Rat
Anesthesiology 4 1995, Vol.82, 963-968.. doi:
Anesthesiology 4 1995, Vol.82, 963-968.. doi:
Key words: Anesthetics, intravenous: ACEA-1021. Anesthetics, volatile: halothane. Neurotransmitters: glutamate; glycine. Receptors: glutamate; glycine.
THE glutamatergic N-methyl-D-aspartate (NMDA) receptor complex has been the focus of intense interest because of its putative role in the pathogenesis of neuronal cell death. Associated with the investigation has been the development of numerous specific competitive and noncompetitive glutamate NMDA receptor antagonists. These compounds (e.g., dizocilpine and CGS19755) have been demonstrated to be neuroprotective against focal cerebral ischemia and to act as anticonvulsant agents. [1-4] .
Concurrent with the development of these compounds has been the demonstration that substantial anesthetic properties can also be elicited, particularly when the NMDA receptor antagonists are administered in large doses. [5-7] Indeed, noncompetitive NMDA receptor antagonism is believed to be the predominant mechanism of anesthetic action for ketamine. [8,9] However, although specific NMDA receptor antagonists have allowed verification of the validity for antagonism of glutamatergic excitation as a mechanism of anesthesia, the clinical utility of these compounds has been limited by their propensity to elicit unfavorable psychotomimetic side effects. [10,11] .
Alternative modes of glutamatergic antagonism are available. For example, glutamatergic coactivation of the AMPA receptor is required for glutamate-mediated postsynaptic depolarization. It has been shown that intravenous administration of the AMPA receptor antagonist NBQX allows substantial reduction in the minimum alveolar concentration (MAC) of halothane, accompanied by a reversible loss of consciousness in the rat. [12] Further examination of this promising mechanism of anesthesia has been limited by the availability of compounds with suitable pharmaceutical formulations and low toxicity profiles when administered in large doses.
Another mechanism for potentially inhibiting glutamatergic excitation lies in the glycine recognition site of the NMDA receptor. Glycine is required to coactivate the NMDA receptor before the associated ionophore becomes permeable. [13-16] In vitro electrophysiologic assays have shown that the recently synthesized compound 5-nitro-6, 7-dichloro-2, 3-quinoxalinedione (ACEA-1021) is a specific potent competitive antagonist at the glycine recognition site. [17] Other studies have indicated that this and other glycine antagonists are potentially neuroprotective in the context of focal cerebral ischemia and possess anticonvulsant properties. [18,19] In contrast to glutamate NMDA receptor antagonists, glycine receptor antagonists appear to be devoid of psychotomimetic properties. [20] .
The purpose of this investigation was to determine whether competitive antagonism of glycine at the strychnine-insensitive NMDA receptor complex exhibits an anesthetic profile consistent with potential clinical utility of this anesthetic mechanism of action.
Materials and Methods
These studies were approved by the University of Iowa Animal Care and Use Committee.
Experiment 1
Male Sprague-Dawley rats (Harlan, Indianapolis, IN), 13 or 14 weeks old, were allowed free access to food and water until the time of the experiment. Animals were weighed and then anesthetized with 3-4% halothane in 50% Oxygen2-balance Nitrogen2. After orotracheal intubation, the lungs were mechanically ventilated (Rodent Ventilator 683, Harvard, South Natick, MA), to maintain arterial CO2tension (PaCO2) between 35 and 45 mmHg. Halothane concentration was then adjusted to 1.3% in 50% Oxygen2-balance Nitrogen2. Right femoral arterial and venous catheters were placed by surgical incision after local skin infiltration with 1% lidocaine. The arterial catheter was used to continuously measure mean arterial pressure (MAP) and to provide blood samples for analysis. The venous catheter was connected to a calibrated infusion pump (Apparatus Syringe infusion pump 22, Harvard) for fluid and drug administration. Rectal temperature was regulated by servomechanism at 37.0 degrees Celsius by surface heating or cooling. After preparation, a 20-min stabilization interval was allowed, and the inspired gas mixture changed to 1.3% halothane in 70% Nitrogen2-balance Oxygen2. Inspired anesthetic agent concentration was continuously monitored with an (5330 Agent Monitor, Ohmeda, Louisville, CO) calibrated according to manufacturer recommendations.
Animals were assigned randomly to one of three groups (n = 6 per group) according to the dose of ACEA-1021 (ACEA Pharmaceuticals, Irvine, CA). ACEA-1021 was prepared as a 0.3% solution dissolved in D5W (5% dextrose in water) with 1% Tween 20 (Fisher Scientific, Fair Lawn, NJ) and 1.38 g/100 ml Tris (hydroxymethyl) aminomethane (Sigma, St. Louis, MO).
- control: An intravenous bolus (over a 10-min period) of vehicle, followed by an intravenous infusion of vehicle at 4.7 ml *symbol* kg sup -1 *symbol* h sup -1.
- ACEA1: ACEA-1021 bolus 20 mg/kg intravenously; infusion rate 14 mg *symbol* kg sup -1 *symbol* h sup -1 (4.7 ml *symbol* kg sup -1 *symbol* h sup -1)
- ACEA2: ACEA-1021 bolus 40 mg/kg intravenously; infusion rate 14 mg *symbol* kg sup -1 *symbol* h sup -1 (4.7 ml *symbol* kg sup -1 *symbol* h sup -1)
MAP was recorded before and 5 and 30 min after initial administration of the drug. In addition, 30 min after starting the infusion, 1 ml arterial blood was withdrawn for determination of plasma ACEA-1021 concentration. Analysis was performed at ACEA Pharmaceuticals by individuals blinded to group assignment. Plasma samples were vortex mixed with an equal volume of 20% trichloroacetic acid diluted in water (Fisher Scientific, St. Louis, MO) to precipitate plasma protein bound drug. The mixture was centrifuged for 5 min at 12,000 g (Microspin 12s, Sorvall Instruments, du Pont, Wilmington, DE). The supernatant was passed through a 0.45-micro meter nylon filter (Acrodisc, Gelman, MI). Ten microliters of sample was injected into a reverse-phase high-performance liquid chromatography column (c18) (Vydac, Hesperia, CA). The absorbance was monitored by an ultraviolet detector at 217 nm. Before analysis of the sample, a standard curve that covered the expected range of sample concentrations was generated using standards with known concentrations of ACEA-1021.
The MAC for halothane was determined starting with an end-tidal concentration of 1.3%. The painful stimulus was a rubbershod 25-cm hemostat clamped to the proximal 2 cm of the tail. [21] The clamp was applied for 60 s, during which time the hemostat was continually rotated across its long axis to simulate a wagging motion of the tail. The clamp was applied to a different site on the tail for each MAC determination. A sustained movement of any of the four extremities occurring during application of the hemostat was considered a positive response.
In the absence of movement, the inspired halothane concentration was reduced by approximately 20% (e.g., to 1.1%). After 20 min of ventilation at the new inspired halothane concentration, MAP, and end-tidal halothane concentration were recorded. The stimulus was then repeated. If the animal failed to respond, the inspired halothane concentration was decreased again by 20% and the sequence was repeated until purposeful movement was observed. The value of the lowest end-tidal concentration at which the rat did not move and that end-tidal value at which movement was observed were averaged and recorded.
End-tidal halothane concentrations were determined as follows. A catheter (polyethylene tubing PE-50, Intramedic, Clay Adams, Parsippany, NJ) was permanently positioned at the distal tip of the endotracheal tube. Small aliquots ([nearly equal] 1 ml for each ventilatory cycle) of expiratory gas were withdrawn into a glass syringe for a total of 35 ml. The aspirated gas was then introduced into a 5330 Agent Monitor (Ohmeda) for analysis.
Experiment 2
Rats were weighed and given pentobarbital (50 mg/kg intraperitoneally). Catheters (polyethylene tubing PE-50, Intramedic) were placed in the right femoral artery and vein by surgical incision and filled with heparin-containing saline. The catheters were capped, tunneled subcutaneously and exteriorized at the nape of the neck. The wounds were closed with suture and infiltrated with 0.125% bupivacaine. The animal was then allowed to awaken and recover for 24 h.
Each rat, breathing room air, was then placed in a Plexiglas cylindrical restrainer (Kent Scientific, Litchfield, CT). The arterial catheter allowed continuous recording of MAP and sampling of blood for analysis of arterial blood gases and pH (pH-blood gas analyzer IL1306, Instrumentation Laboratory, Lexington, MA). The venous catheter was used for drug infusion. The animals were assigned randomly to one of three groups (n = 6 per group). Vehicle and drug infusion regimens for the three groups (control, ACEA1, and ACEA2) were identical to those described above in experiment 1.
After a 15-min interval for acclimation to the restraining apparatus, baseline MAP, arterial Oxygen2tension (PaO2). PaCO2, and pHawere determined. The designated bolus and infusion regimen was then initiated. To reflect the temporal events occurring in experiment 1, respective intravenous infusions were continued for 30 min. At 30 min after onset of infusion, MAP, PaOsub 2, PaCO2, and pHadeterminations were repeated. The infusion was then discontinued. The animal was removed from the restraining apparatus and placed on its side in a cage and observed. The interval required for spontaneous recovery of the righting reflex was recorded.
To test whether ACEA-1021 decreased MAC, increased time to recovery of righting reflex, increased PaCO2(experiment 2), or decreased MAP (experiment 2), we used one-sided linear correlation coefficients between doses (milligrams per kilogram) and responses. [22] We did not include the 0-mg/kg dose in the righting reflex analysis because the response was the same at 20 mg/kg (i.e., no loss of righting reflex). Statistical power to detect a decrease in MAP, as the dose of ACEA-1021 was increased from 0 to 40 mg/kg, was calculated post hoc, using a one-tailed t test with alpha = 0.05. Values are reported as mean plus/minus standard deviation.
Results
Experiment 1
Physiologic data are presented in Table 1. Arterial pH, Pa sub CO2, PaO2and rectal temperature were similar between groups at time of MAC determination. MAP values were least in those rats receiving vehicle only.
Table 1. Physiologic Values for Experiment 1
Image not available
Table 1. Physiologic Values for Experiment 1
×
ACEA-1021 decreased halothane MAC in a dose-dependent manner (control, 0.95 plus/minus 0.15 vol%; ACEA1, 0.50 plus/minus 0.14 vol%; ACEA2, 0.14 plus/minus 0.16 vol%; r = -0.92, P < 0.01) (Figure 1). As expected, plasma concentrations of ACEA-1021 increased with larger doses of the drug (control, 0 micro gram/ml; ACEA1, 72 plus/minus 5 micro gram/ml; ACEA2, 84 plus/minus 10 micro gram/ml).
Figure 1. Minimum alveolar concentration (MAC) for halothane as a function of the dose of the competitive glycine receptor antagonist 5-nitro-6,7-dichloro-2,3-quinoxalinedione (ACEA-1021). Each point depicts values for an individual rat. ACEA1= ACEA-1021 bolus 20 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1; ACEA2= ACEA-1021 bolus 40 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1. Mean plus/minus SD MAC for halothane: control group, 0.95 plus/minus 0.15 vol%; ACEA, 0.50 plus/minus 0.14 vol%; ACEA2, 0.14 plus/minus 0.16 vol%. Pearson correlation coefficient, r = -0.92; t = 9.31; P = 3 x 108.
Figure 1. Minimum alveolar concentration (MAC) for halothane as a function of the dose of the competitive glycine receptor antagonist 5-nitro-6,7-dichloro-2,3-quinoxalinedione (ACEA-1021). Each point depicts values for an individual rat. ACEA1= ACEA-1021 bolus 20 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1; ACEA2= ACEA-1021 bolus 40 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1. Mean plus/minus SD MAC for halothane: control group, 0.95 plus/minus 0.15 vol%; ACEA, 0.50 plus/minus 0.14 vol%; ACEA2, 0.14 plus/minus 0.16 vol%. Pearson correlation coefficient, r = -0.92; t = 9.31; P = 3 x 108.
Figure 1. Minimum alveolar concentration (MAC) for halothane as a function of the dose of the competitive glycine receptor antagonist 5-nitro-6,7-dichloro-2,3-quinoxalinedione (ACEA-1021). Each point depicts values for an individual rat. ACEA1= ACEA-1021 bolus 20 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1; ACEA2= ACEA-1021 bolus 40 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1. Mean plus/minus SD MAC for halothane: control group, 0.95 plus/minus 0.15 vol%; ACEA, 0.50 plus/minus 0.14 vol%; ACEA2, 0.14 plus/minus 0.16 vol%. Pearson correlation coefficient, r = -0.92; t = 9.31; P = 3 x 108.
×
Experiment 2
Physiologic values are presented in Table 2. Baseline values for MAP, pH2, PaCO2, PaO2, and body weight were similar between groups. At completion of the bolus dose of ACEA-1021 or vehicle, there were no differences between groups for MAP. Thirty min after onset of infusion, MAP remained similar between the control, ACEA1, and ACEA2groups (r = -0.8, P = 0.38). We had 80% power to detect a decrease in MAP of 14 mmHg. In contrast, PaCOsub 2 increased in a dose-dependent fashion with administration of ACEA-1021 (r = 0.96, P < 0.01). Nevertheless, there was no decrease in the PaO2.
Table 2. Physiologic Values for Experiment 2
Image not available
Table 2. Physiologic Values for Experiment 2
×
After 30 min of ACEA-1021 (or vehicle) administration, rats in the control and ACEA1groups showed no evidence of sedation and had no impairment of the righting reflex. In contrast, all rats in the ACEA2group were deeply sedated and had a loss of the righting reflex (P < 0.01). Time to recovery of righting reflex after discontinuation of ACEA-1021 in these animals was 30 plus/minus 7 min.
Discussion
The administration of the glycine-receptor antagonist ACEA-1021 resulted in a dose-dependent reduction of halothane MAC in the rat. Mean maximal reduction in MAC was 85%. Of greater interest was the observation that in five of six animals receiving the largest dose of ACEA-1021 MAC was essentially zero. In these animals, halothane was purposely left discontinued for as long as 1 h (with continued ACEA-1021 infusion), yet no response to noxious stimuli was observed. Cohort rats, undergoing an identical infusion regimen (without halothane anesthesia), were deeply sedated but remained hemodynamically stable, although spontaneous ventilation was moderately depressed.
The magnitude of MAC reduction by glycine receptor antagonism was substantially greater than has been previously reported for compounds implicated in the antagonism of glutamatergic neurotransmission. Aside from ketamine, the original work examining effects of glutamate antagonists on volatile anesthetic requirements was that of Scheller et al. [5] In their experiment the noncompetitive NMDA receptor antagonist dizocilpine reduced isoflurane MAC by 65% in the rabbit albeit no attempt was made to define a ceiling effect for the drug. Other work has demonstrated that neuroprotective doses of a variety of NMDA receptor antagonists (dizocilpine, CGS19755, and CPPene) reduce isoflurane MAC by approximately 50%. [6] Using larger doses of CPPene in the rat, Perkins and Morrow reported a ceiling effect for the drug as a 78% reduction in halothane MAC.* Previous work in our laboratory has focused on antagonism of glutamate at the AMPA receptor with NBQX; the maximal reduction in halothane MAC that could be obtained was approximately 60%. [12] Toxic side effects precluded administration of larger doses of the drug. Finally, presynaptic inhibition of glutamate release with the anticonvulsant agent riluzole again caused an approximately 50% reduction in halothane MAC in the rat. [7] .
Thus, the results from this experiment are encouraging that a reversible deep anesthetic state can be achieved solely through antagonism of glycine at the NMDA receptor complex. Several considerations, however, remain to be resolved. First, current pharmaceutical development of glycine receptor antagonists is at a stage where bioavailability remains a problem and the magnitude of specificity for the glycine receptor by these agents is largely unpublished. It is likely that weak coantagonism of glutamate at the kainate (inhibition constant Ki= 92 micro Meter) or AMPA (Ki= 21 micro Meter) receptor (as opposed to the strychnine-insensitive glycine receptor, K sub i = 0.007 micro Meter) is a property of these compounds when administered in large doses (although there is no affinity for ACEA-1021 and either the strychnine-sensitive glycine receptor or gamma-aminobutyric acid A or gamma-aminobutyric acid B receptors). [23] At least three reports have implicated a synergism between compounds that are targeted to antagonize glutamate at the NMDA or AMPA receptor, [24-26] leaving open the possibility that the magnitude of effect we observed was attributable to a combined antagonism of different receptor types.
Furthermore, an important question has been raised with respect to what MAC actually represents. It is unsettling to conclude that a drug provides anesthesia simply on the basis of a MAC reduction study, given the work of Rampil et al. [27-29] In a series of ablation experiments, the possible anatomic locus of MAC has been moved progressively caudal in the neuroaxis, indicating that MAC represents a spinal phenomenon. [27-29] The spinal cord is richly endowed with glutamatergic neurotransmitters and to some extent, the results observed in this experiment may be directly attributable to spinal effects of the glycine antagonist on neurotransmission. However, this investigation has identified a potent sedative effect for ACEA-1021 suggesting a central role, at least in part, for the anesthetic effects of glycine receptor antagonists.
Finally, we cannot be sure of the effect of ACEA-1021 on the efficiency of the neuromuscular junction. There is little obvious reason to expect this class of compounds would exert neuromuscular blockade, which might have precluded movement to the noxious stimuli. No attempt was made to assess the integrity of the neuromuscular junction in this experiment. However, given the relatively modest compromise of ventilation observed (PaCO248 plus/minus 2 mmHg and PaOsub 2 96 plus/minus 6 mmHg) in rats spontaneously breathing room air at the largest dose of ACEA-1021 it seems unlikely that substantial neuromuscular blockade was present.
In conclusion, competitive antagonism at the glycine receptor by intravenous ACEA-1021 was effective in reducing the halothane MAC in a dose-dependent fashion. There was no evidence of hemodynamic compromise at doses sufficient to reduce halothane MAC by as much as 85%. In contrast, mild hypercapnia was observed without hypoxemia with the largest doses administered. Given the known specificity of ACEA-1021, the data show that competitive glycine antagonism at the strychnine-insensitive NMDA receptor complex modulates anesthetic potency as measured by the reduction in halothane MAC. The results implicate glycine antagonism at the strychnine-insensitive glycine recognition site of the NMDA receptor complex as a site for potentiation of general anesthetic action. It is hoped that this work will provide a basis for the development of agents that in addition to having anesthetic potential will be neuroprotective.
The authors are grateful to Michael M. Todd, M.D. for his thoughtful contributions to discussions. The authors are grateful to Minthan Tran, Ph.D. and Steve Disper for analysis of plasma ACEA-1021 concentrations.
*Perkins W, Morrow D: A dose dependent reduction in halothane M.A.C. in rats with a competitive N-methyl-D-aspartate (NMDA) receptor antagonist (abstract). Anesth Analg 74:S234, 1992.
REFERENCES
Oyzuart E, Graham D, Woodruff G, McCulloch J: Protective effect of the glutamate antagonist MK-801 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab 8:138-143, 1988.
Simon R, Shiraishi K: N-methyl-D-aspartate antagonist reduces stroke size and regional glucose metabolism. Ann Neurol 27:606-611, 1990.
Faingold C, Randall M, Naritoku D, Anderson C: Noncompetitive and competitive NMDA antagonists exert anticonvulsant effects by actions on different sites within the neuronal network for audiogenic seizures. Exp Neurol 119:198-204, 1993.
Gilbert M: The NMDA antagonist MK-801 suppresses behavioral seizures, augments afterdischarges, but does not block development of perforant path kindling. Epilepsy Res 17:145-156, 1994.
Scheller M, Zornow M, Fleischer J, Shearman G, Greber T: The noncompetitive N-methyl-D-aspartate receptor antagonist MK-801 profoundly reduces volatile anesthetic requirements in rabbits. Neuropharmacology 28:677-681, 1989.
Kuroda Y, Strebel S, Rafferty C, Bullock R: Neuroprotective doses of N-methyl-D-aspartate receptor antagonists profoundly reduce the minimum alveolar anesthetic concentration (MAC) for isoflurane in rats. Anesth Analg 77:795-800, 1993.
Mantz J, Cheramy A, Thierry A-M, Glowinski J, Desmonts J-M: Anesthetic properties of riluzole (54272 RP), a new inhibitor of glutamate neurotransmission. ANESTHESIOLOGY 76:844-848, 1992.
Anis N, Berry S, Burton N, Lodge D: The dissociative anesthetics ketamine and phencyclidine selectively reduce excitation of central mammalian neurones by N-methylaspartate. Br J Pharmacol 79:565-575, 1983.
Yamamura T, Harada K, Okamura A, Kemmotsu O: Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor? ANESTHESIOLOGY 72:704-710, 1990.
Willetts J, Balster R, Leander J: The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11:423-428, 1990.
Grotta J: Safety and tolerability of the glutamate antagonist CGS19755 (abstract). Stroke 25:255, 1994.
McFarlane C, Warner D, Todd M, Nordholm L: AMPA receptor competitive antagonism reduces halothane MAC in rats. ANESTHESIOLOGY 77:1165-1170, 1992.
Johnson J, Ascher P: Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325:529-531, 1987.
Forsythe I, Westbrook G, Mayer M: Modulation of excitatory synaptic transmission by glycine and zinc in cultures of mouse hippocampal neurons. J Neurosci 8:3733-3741, 1988.
Dalkara T, Erdemli G, Barun S, Onur R: Glycine is required for NMDA receptor activation: Electrophysiological evidence from intact rat hippocampus. Brain Res 576:197-202, 1992.
Lester R, Tong G, Jahr C: Interactions between the glycine and glutamate binding sites of the NMDA receptor. J Neurosci 13:1088-1096, 1993.
Cai S, Dinsmore C, Gee K, Glenn A, Huang J, Johnson B, Kher S, Lu Y, Oldfield P, Marek P, Zheng H, Weber E, Keana J: Synthesis and activity of substituted quinoxaline-2,3-diones as antagonists for the glycine/NMDA receptor (abstract). J Neurosci 19:296.11, 1993.
Warner D, Wu H, Ludwig P, Todd M: Glycine NMDA receptor antagonism reduces focal but not global ischemic brain damage in the rat (abstract). J Neurosci 19:674.3, 1993.
Nichols A, Yielding K: Anticonvulsant activity of antagonists for the NMDA-associated glycine binding site. Mol Chem Neuropathol 19:269-282, 1993.
Balster R, Grech D, Mansbach R, Li H, Weber E: Behavioral studies of the novel glycine-site NMDA antagonists ACEA 1011 and ACEA 1021 in rats (abstract). J Neurosci 19:197.16, 1993.
Eger E II, Saidman L, Brandstater B: Minimum alveolar anesthetic concentration: A standard of anesthetic potency. ANESTHESIOLOGY 26:756-763, 1965.
Neter J, Wasserman W, Kutner M: Applied Linear Regression Models. Homewood, Richard D, Irwin, 1983, pp 328-339.
Woodward R, Huettner J, Guastella J. Weber E: In vitro pharmacological characterization of ACEA-1021: A potent NMDA receptor glycine site antagonist (abstract). J Neurosci 19:296.14, 1993.
Loscher W, Rundfeldt C, Honack D: Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor NBQX in the kindling model of epilepsy. Eur J Pharmacol 5:1545-1550, 1993.
Lippert K, Welsch M, Krieglstein J: Over-additive protective effect of dizocilpine and NBQX against neuronal damage. Eur J Pharmacol 253:207-213, 1994.
McFarlane C, Warner DS, Dexter F, Todd MM: Interaction between NMDA and AMPA receptor antagonists during halothane anesthesia in the rat (abstract). J Neurosurg Anesth 6:328, 1994.
Rampil I, Mason P, Singh H: Anesthetic potency (MAC) is independent of forebrain structures in the rat. ANESTHESIOLOGY 78:707-712, 1993.
Rampil I: `F-waves': A nonsynaptic, but sensitive indicator of anesthetic effect in rats (abstract). Anesth Analg 78:S350, 1994.
Rampil I: Anesthetic potency is not altered after hypothermic spinal cord transection in rats. ANESTHESIOLOGY 80:606-610, 1994.
Figure 1. Minimum alveolar concentration (MAC) for halothane as a function of the dose of the competitive glycine receptor antagonist 5-nitro-6,7-dichloro-2,3-quinoxalinedione (ACEA-1021). Each point depicts values for an individual rat. ACEA1= ACEA-1021 bolus 20 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1; ACEA2= ACEA-1021 bolus 40 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1. Mean plus/minus SD MAC for halothane: control group, 0.95 plus/minus 0.15 vol%; ACEA, 0.50 plus/minus 0.14 vol%; ACEA2, 0.14 plus/minus 0.16 vol%. Pearson correlation coefficient, r = -0.92; t = 9.31; P = 3 x 108.
Figure 1. Minimum alveolar concentration (MAC) for halothane as a function of the dose of the competitive glycine receptor antagonist 5-nitro-6,7-dichloro-2,3-quinoxalinedione (ACEA-1021). Each point depicts values for an individual rat. ACEA1= ACEA-1021 bolus 20 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1; ACEA2= ACEA-1021 bolus 40 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1. Mean plus/minus SD MAC for halothane: control group, 0.95 plus/minus 0.15 vol%; ACEA, 0.50 plus/minus 0.14 vol%; ACEA2, 0.14 plus/minus 0.16 vol%. Pearson correlation coefficient, r = -0.92; t = 9.31; P = 3 x 108.
Figure 1. Minimum alveolar concentration (MAC) for halothane as a function of the dose of the competitive glycine receptor antagonist 5-nitro-6,7-dichloro-2,3-quinoxalinedione (ACEA-1021). Each point depicts values for an individual rat. ACEA1= ACEA-1021 bolus 20 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1; ACEA2= ACEA-1021 bolus 40 mg/kg intravenously, infusion 14 mg *symbol* kg sup -1 *symbol* h sup -1. Mean plus/minus SD MAC for halothane: control group, 0.95 plus/minus 0.15 vol%; ACEA, 0.50 plus/minus 0.14 vol%; ACEA2, 0.14 plus/minus 0.16 vol%. Pearson correlation coefficient, r = -0.92; t = 9.31; P = 3 x 108.
×
Table 1. Physiologic Values for Experiment 1
Image not available
Table 1. Physiologic Values for Experiment 1
×
Table 2. Physiologic Values for Experiment 2
Image not available
Table 2. Physiologic Values for Experiment 2
×